OBI Pharma, Inc.
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Company type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 6F, No. 508, Sec. 7, Zhongxiao E RdNangang District, Taipei City, 115, Taiwan |
Key people | Kung-Yee Liang (Chairman) Heidi Wang (CEO) |
| Website | www.obipharma.com |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).